Clinical Validation of a Multi-Biomarker Assay for the Evaluation of Chronic Pain Patients in a Cross-Sectional, Observational Study

Pain and Therapy

John E. Beresh¹  Timothy R. Deer²  Nathan Miller³  Bradley M. Cotten⁴  Joshua Gunn⁴  Melissa M. Hill⁴  Jason E. Pope⁵  George Girardi⁶  Kasra Amirdelfan⁷  Pankaj Mehta⁸  Douglas Dobecki⁹ 

[1] Beresh Pain Management, Inc;Center for Pain Relief;Coastal Pain and Spinal Diagnostics;Ethos Research and Development, LLC;Evolve Restorative Center;Front Range Pain Medicine;IPM Medical Group;Pain Specialists of Austin;San Diego Pain Institute;

关键词: Biomarker;    Inflammation;    Kynurenine;    Micronutrient;    Pain;   

DOI  :  10.1007/s40122-020-00175-3

来源: DOAJ

【 摘 要 】

Abstract Introduction Chronic pain assessment and post-treatment evaluation continues to be challenging due to a lack of validated, objective tools to measure patient outcomes. Validation of mechanistic pain biomarkers would allow clinicians to objectively identify abnormal biochemistry contributing to painful symptoms. Methods We describe the clinical validation of a multi-biomarker assay with algorithmic analysis known as the Foundation Pain Index (FPI) in diverse cohorts of chronic pain patients in a prospective, cross-sectional, observational validation study. Levels of 11 urinary pain biomarkers were measured and tabulated using a proprietary algorithm to generate FPI scores for chronic pain subjects (N = 153) and age- and sex-matched pain-free controls (N = 334). Results FPI scores were significantly correlated with the 36-Item Short Form Health Survey (SF-36) scores among chronic pain subjects (P value < 0.015) and specific components of SF-36, including emotional well-being, limitations due to emotional problems, and general health (P value < 0.05). Area under ROC analysis (AUROC) revealed FPI to accurately distinguish biomarker profiles between pain-free and chronic pain cohorts (AUROC: 0.7490, P value < 0.0001) as well as the SF-36 scores between chronic pain subjects with low vs. high FPI scores (AUROC: 0.7715, P value < 0.01). Conclusions Our findings establish the validity and discriminatory power of a novel multi-biomarker test that evaluates the role of biochemistry in chronic pain and correlates with clinical assessments of patients. This test provides novel, reproducible, objective data which may pave the way for non-opioid therapeutic strategies to treat chronic pain.

【 授权许可】

Unknown